Drug or technology
7 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
AUG 13, 2026 · OBSERVATIONAL STUDY
ClinicalTrials.gov
This is an ongoing observational study with very small planned enrollment (n=12) investigating pharmacokinetic changes; no results are yet reported in the registry record.
JUL 13, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval action for lamotrigine orally disintegrating tablet labeling; does not report clinical trial data or efficacy evidence.
MAY 12, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of labeling changes for lamotrigine tablets; regulatory action without clinical trial data or efficacy claims.
APR 13, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
This is an FDA supplemental approval action for a labeling change to lamotrigine tablets; it documents a regulatory decision, not clinical trial evidence.
APR 10, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of labeling changes for lamotrigine kit; a regulatory action without clinical trial data reported.
APR 10, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a labeling change for lamotrigine generic tablets; describes a regulatory action, not clinical evidence of efficacy or safety.
APR 9, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of labeling changes for lamotrigine tablets; this is a regulatory action record, not a clinical trial, and does not report efficacy or safety trial data.